Takeda walks away from Omontys

Share this article:

Takeda and Affymax are parting ways. PMLive reports that Takeda is withdrawing its US marketing application for the anemia drug Omontys and that Affymax is not looking to pick the marketing rights up.

The companies had to recall the drug last year after several patient deaths and allergic reactions. Takeda told PMLive that it looked into the reactions and found they could not be attributed to quality or manufacturing issues.

PMLive says Affymax had three employees as of March, and was running a deficit of around $560 million.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.